

Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis

Reade B. Roberts*[†], Lu Min[‡], M. Kay Washington^{§¶}, Sandra J. Olsen[§], Stephen H. Settle[‡], Robert J. Coffey*^{¶||}, and David W. Threadgill*^{†¶||**}

Departments of *Cell Biology, [§]Pathology, and [‡]Medicine, and [¶]Vanderbilt-Ingram Cancer Center, Vanderbilt University and ^{||}Veterans Affairs Medical Center, 1161 21st Avenue South, Nashville, TN 37232

Communicated by James E. Womack, Texas A & M University, College Station, TX, December 17, 2001 (received for review June 3, 2001)

We used the hypomorphic *Egfr*^{wa2} allele to genetically examine the impact of impaired epidermal growth factor receptor (Egfr) signaling on the *Apc*^{Min} mouse model of familial adenomatous polyposis. Transfer of the *Apc*^{Min} allele onto a homozygous *Egfr*^{wa2} background results in a 90% reduction in intestinal polyp number relative to *Apc*^{Min} mice carrying a wild-type *Egfr* allele. This *Egfr* effect is potentially synergistic with the actions of the modifier-of-min (*Mom1*) locus. Surprisingly, the size, expansion, and pathological progression of the polyps appear *Egfr*-independent. Histological examination of the ilea of younger animals revealed no differences in the number of microadenomas, the presumptive precursor lesions to gross intestinal polyps. Pharmacological inhibition with EKI-785, an *Egfr* tyrosine kinase inhibitor, produced similar results in the *Apc*^{Min} model. These data suggest that normal *Egfr* activity is required for establishment of intestinal tumors in the *Apc*^{Min} model between initiation and subsequent expansion of initiated tumors. The role of *Egfr* signaling during later stages of tumorigenesis was examined by using nude mice xenografts of two human colorectal cancer cell lines. Treatment with EKI-785 produced a dose-dependent reduction in tumor growth, suggesting that *Egfr* inhibitors may be useful for advanced colorectal cancer treatment.

Epidermal growth factor receptor (Egfr) is the prototypical member of the ErbB family of ligand-activated receptor tyrosine kinases (1). Mice homozygous for the targeted null *Egfr*^{tm1Mag} allele show strain-dependent lethality (2). Genetic backgrounds supporting survival of *Egfr*^{tm1Mag} homozygous mutants to term demonstrate the importance of *Egfr* for epithelial homeostasis (2–4); neonatal mice lacking *Egfr* maintain a robust proliferative compartment but develop disorganized cryptal architecture of the lower gastrointestinal (GI) tract (2) and hemorrhagic enteritis (4). The hypomorphic *Egfr*^{wa2} allele contains a single nucleotide mutation producing a valine to glycine amino acid substitution in the kinase domain, resulting in up to a 90% reduction in kinase activity (5, 6). Unlike *Egfr*^{tm1Mag} homozygotes, mice homozygous for *Egfr*^{wa2} are fully viable, although they manifest skin epithelium and mammary gland defects. Upon perturbation, *Egfr*^{wa2} homozygotes exhibit subtle GI phenotypes; *Egfr*^{wa2} mice exhibit delayed intestinal adaptation and reestablishment of epithelial homeostasis after intestinal resection (7) as well as increased susceptibility to dextran sulfate-induced colitis (8). Furthermore, ectopic *Egfr* activation promotes increased intestinal epithelial cell proliferation and crypt size but a decrease in crypt fission rates (9).

Overexpression of *Egfr*, the most commonly observed cancer-associated misregulation in *Egfr* signaling, correlates with poor prognosis in a number of cancers including breast, ovarian, and head and neck (10–12). Because *Egfr* activation can promote proliferation and maintain survival, amplification of receptor

signaling by means of overexpression may promote tumor growth and resistance to apoptosis. *Egfr* signaling up-regulates its cognate ligands, creating autocrine loops that maintain and amplify levels of *Egfr* activity (13). For instance, although *Egfr* activity is not required for the initiation of squamous papillomas derived from *ras*^{H1a}-transformed keratinocytes, an *Egfr* autocrine loop is essential for maintenance of papilloma growth and prevention of terminal differentiation of dysplastic cells (14, 15). Similarly, mice with impaired *Egfr* signaling are resistant to skin papillomas induced by ectopic expression of the downstream *Egfr* pathway member *Sos1* (16). In the GI tract, expression of *Egfr* and its ligands is often higher in tumors than in surrounding normal tissue (17). Furthermore, the level of *Egfr* expression generally correlates with colon cancer progression and metastatic potential (18–20). In tumor cells *Egfr* polarity may be lost, providing an additional avenue for altered *Egfr* action influencing abnormal cell growth (18).

Because in part of evidence implicating hyperactivity of *Egfr* in a variety of human disease states, a number of *Egfr* inhibitors have been developed as potential therapeutic agents (21). One such agent is EKI-785, a small molecule inhibitor that irreversibly binds the ATP-binding region of *Egfr*, efficiently suppressing *Egfr* kinase activity (22). EKI-785 has been used to reduce severity of polycystic kidney disease in mouse models (23) and to reduce polyp number in the *Apc*^{Min} mouse model of familial adenomatous polyposis (24). Interestingly, a conflicting report showed no effect on polyp multiplicity in the *Apc*^{Min} model by using a similar *Egfr* inhibitor, *N*-[4-(3-chloro-4-fluorophenylamino)-quinazolin-6-yl]-acrylamide (CFPQA) (25). Mice heterozygous for the *Apc*^{Min} truncation mutation exhibit tens to hundreds of intestinal adenomas, primarily in the small bowel (26). Tumor multiplicity in *Apc*^{Min} animals is highly influenced by genetic background. For example, the *Mom1* locus accounts for ~50% of strain variability in the *Apc*^{Min} phenotype and contains at least two genes capable of altering *Apc*^{Min} tumor biology (27). Polyps arising in *Apc*^{Min} mice exhibit strong nuclear β -catenin immunoreactivity, a molecular hallmark of the majority of human colorectal adenomas and carcinomas (28, 29). We have used a combination of genetic and pharmacological approaches to resolve conflicting pharmacological reports and

Abbreviations: Apc, adenomatous polyposis coli; CRC, colorectal cancer; Egfr, epidermal growth factor receptor; EKI, *Egfr* kinase inhibitor; GI, gastrointestinal; H&E, hematoxylin and eosin; Mom, modifier-of-min; wt, wild type.

[†]Present address: Lineberger Cancer Center, Room 12109, Department of Genetics, CB 7264, University of North Carolina, Chapel Hill, NC 27599.

**To whom reprint requests should be addressed. E-mail: dwt@med.unc.edu.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

to directly examine the temporal dependency on Egfr signaling during adenomatous polyposis coli (Apc)-mediated intestinal tumorigenesis.

Materials and Methods

Mice. B6EiC3H-*Egfr^{wa2}* and C57BL/6J-*Apc^{Min}* mice were obtained from The Jackson Laboratory. *Egfr^{tm1Mag}* (previously designated *Egfr^{tm1Cwr}*) was maintained on 129S6/SvEvTAC and CD1-mixed genetic backgrounds segregating *Mom1^s* and *Mom1^r* alleles. A line of mice segregating *Egfr^{wa2}*, *Egfr^{tm1Mag}*, and *Mom1^s*, *Mom1^r* was established by crossing their respective carriers. This line was then bred to the C57BL/6J-*Apc^{Min}* line and the offspring intercrossed to generate progeny segregating alleles at each locus. Mice were given Purina Mills LabDiet 5010 and water ad libitum under specific pathogen-free conditions in an American Association for the Accreditation of Laboratory Animal Care-approved facility, and were killed by CO₂ asphyxiation.

Genotyping. Mice were genotyped for *Egfr^{wa2}* by PCR amplifying a 170-bp region (primers: 5'-CCCAGAAAGGGATATGCG-3' and 5'-GCAACCGTAGGGCATGAG-3') and digesting with *FokI* to produce an uncut 170-bp or cut 75- and 95-bp fragments diagnostic for wild-type (wt) *Egfr* and *Egfr^{wa2}* alleles, respectively. Mice were genotyped for *Egfr^{tm1Mag}* and *Apc^{Min}* alleles as reported (2, 30). Mice were genotyped for *Mom1* status by PCR amplifying a 500-bp region (primers: 5'-GTCCAAGGGAA-CATTGCG-3' and 5'-AGAACAGGTGATTTGGCCC-3') and digesting with *BamHI* to produce diagnostic fragments of 100 and 400 bp for the *Mom1^r* allele and 500 bp for the *Mom1^s* allele.

Macroadenoma Counts. The GI tract from pylorus to rectum was removed. Small intestine was cut into thirds, and the caecum and colon were separated. Segments were gently flushed with PBS to remove fecal material, cut longitudinally, splayed flat on Whatmann 3MM paper, and fixed overnight at 4°C in 4% paraformaldehyde. Polyp counts and diameter measurements were made under a dissection microscope with an in-scope micrometer, allowing detection of polyps >0.3 mm in diameter. Representative polyps were histologically confirmed by excision with surrounding normal tissue. The tissue was dehydrated, embedded in paraffin, and sectioned perpendicular to the plane of the GI tract. Hematoxylin and eosin (H&E) staining was used to examine tumor morphology.

Microadenoma Counts. Ilea of 4-wk-old mice were dissected, gently flushed with PBS, splayed open, and rolled into a jelly roll before fixing in 4% paraformaldehyde. The processed ilea were embedded in paraffin and 7- μ m sections cut at 50- μ m intervals through 1,600 μ m of tissue. Sections were stained with H&E and scored morphologically for microadenomas, characterized by alterations in cryptal architecture and nuclear cytology as described in results. Relative microadenoma score was expressed as the total number of microadenomas scored (nonoverlapping morphological and normalized nuclear β -catenin counts) divided by the number of slides for each case.

Immunohistochemistry. Microwave antigen retrieval with citrate buffer and the Mouse-on-Mouse kit (Vector Laboratories) were used in conjunction with primary Ab for β -catenin (Transduction Laboratories, Lexington, KY, clone 14, 1:500 dilution) or Ki67 (NovoCastra, Newcastle, U.K., 1:100 dilution). Visualization was with diaminobenzidine substrate. Sections at 200- μ m intervals were examined in a blinded fashion for nuclear β -catenin and compared to adjacent H&E sections.

Autoradiography. Mice were injected i.p. 6 h before killing with 1 μ Ci methyl-[³H]thymidine/gm body weight in saline. Tissues were fixed as described above and sections were exposed to




Fig. 1. Intestinal lesion numbers in *Apc^{Min}* mice vs. *Egfr* status. (A) Macroadenoma analysis. Each dot represents polyp number from a single 3-mo-old mouse with horizontal lines representing means. *Egfr⁺* designates mice carrying a wt *Egfr* allele (genotypes *Egfr^{+/+}*, *Egfr^{+/wa2}*, and *Egfr^{+/tm1Mag}*; $n = 28$); *Egfr^{wa2}* designates mice with the waved-2 phenotype (genotypes *Egfr^{wa2/wa2}* and *Egfr^{wa2/tm1Mag}*; $n = 37$). (B) Microadenoma analysis. Each dot represents the ileal microadenoma score of a single, 1-mo-old mouse (*Egfr^{+/wa2}*, $n = 14$; *Egfr^{wa2/wa2}*, $n = 10$).

Kodak NTB2 emulsion for 4 wk before developing with Kodak D-19. Counterstain was 0.2% toluidine blue.

Pharmacologic Treatment. EKI-785 obtained from Philip Frost (Wyeth-Ayerst) was suspended at 25 μ g/ μ l in DMSO. Starting at 1 mo of age, mice were injected i.p. every other day with either 50 mg EKI-785 per kg body weight (treated cohort) or with an equivalent volume of DMSO alone (control cohort). Animals were killed at 3 mo of age and GI tracts were processed as described above.

Human Colon Cancer Cell Lines and Xenografts. Cell lines HCA-7 Colony 29 and HCT-116 were obtained from Susan Kirkland (Imperial College, London; ref. 31) and American Type Culture Collection, respectively, and injected into dorsal s.c. tissue of athymic nude mice (Harlan Sprague-Dawley) as described (32). When tumors reached 150 mm³, mice received i.p. injections of EKI-785 or DMSO three times weekly. Tumor volume was determined by external measurement according to the equation: volume = length \times width² \times 0.5.

Statistics. The nonparametric Mann-Whitney *U* test was used to analyze all comparisons except polyp growth rate and the *Mom1-Egfr* interaction, analyzed with the paired Wilcoxon ranked sign test and ANOVA, respectively. One-sided *P* values are given.

Results

Egfr-Dependent Intestinal Adenoma Multiplicity. Because mice lacking *Egfr* are nonviable, the *Egfr^{wa2}* hypomorphic allele was used to test the importance of Egfr signaling during Apc-mediated intestinal tumorigenesis. *Apc^{Min}* heterozygous mice (3-mo-old) exhibiting a waved coat, resulting from homozygosity for *Egfr^{wa2}* or compound heterozygosity for *Egfr^{wa2/tm1Mag}*, developed on average 10-fold fewer macroscopic (>0.3 mm) polyps compared to nonwaved *Apc^{Min}* littermates (4.6 ± 8.7 vs. 40.9 ± 27.2 ; $P < 0.0001$; Fig. 1A). The majority of *Apc^{Min}*, *Egfr^{wa2}* animals had zero or only one detectable polyp. Histological analysis of polyps revealed no morphological differences related to *Egfr* genotype. The average polyp number was 4.6 for both *Apc^{Min}*, *Egfr^{wa2/wa2}*

Table 1. Mean polyp number in 3-mo-old *Apc^{Min}* animals by *Egfr* and *Mom1* genotype

Genotype	<i>Egfr^{+/+}</i> and <i>Egfr^{wa2/+}</i>	<i>Egfr^{wa2/wa2}</i> and <i>Egfr^{wa2/tm1Mag}</i>
<i>Mom1^{ts}</i>	58.5 (100%)*, n = 14	7.9 (13.6%), n = 17
<i>Mom1^{tr}</i> and <i>Mom1^{rs}</i>	24.5 (41.8%), n = 13	1.8 (3.1%), n = 18

*Percentages relative to *Mom1^{ts}, Egfr⁺* genotype; $P < 0.0001$ for all genotype comparisons.

($n = 25$) and *Apc^{Min}, Egfr^{wa2/tm1Mag}* ($n = 9$) animals, proving that the reduction in Apc-mediated polyp number was specific to *Egfr* and not because of a linked chromosomal effect; the *Egfr^{wa2}* allele is carried on a C57BL/6J chromosome whereas the *Egfr^{tm1Mag}* allele is carried on a 129S6/SvEvTAC chromosome. No differences in polyp number were observed between mice carrying one or two wt *Egfr* alleles. Polyp distribution along the length of the lower GI tract was not altered by *Egfr* genotype (data not shown); the *Egfr*-dependent, 10-fold reduction in polyp number was observed in all regions of the small intestine and colon.

Interaction Between *Egfr* and *Mom1*. The genetic background used in these experiments was segregating *Mom1^r* and *Mom1^s*, resistant and susceptible alleles of the *Mom1* locus, respectively. As previously reported (33), when compared to *Mom1^s* homozygotes, the semidominant *Mom1^r* allele reduces polyp multiplicity $\approx 50\%$ in *Apc^{Min}* mice with a wt *Egfr* allele (Table 1). Interestingly, the *Egfr^{wa2}* background only reduces polyp number 7-fold in *Mom1^s* homozygous animals whereas animals carrying a *Mom1^r* allele exhibit a 14-fold reduction in polyp number. Furthermore, *Mom1^r* and *Egfr^{wa2}* together would appear to have a much greater effect on the *Apc^{Min}* phenotype than would be predicted from a simple additive effect of the two alleles; *Mom1^r, Egfr^{wa2}* mice show greater than a 30-fold reduction in Apc-mediated polyp number over *Mom1^s* homozygous mice on a wt *Egfr* background. However, ANOVA analysis shows this potential interaction to be statistically nonsignificant ($P = 0.34$). Precise quantitation of the combined *Mom1^r* and *Egfr^{wa2}* affect on *Apc^{Min}* phenotype will require measurement on isogenic backgrounds.

***Egfr*-Independent Intestinal Adenoma Initiation.** Previous reports have suggested that the majority of polyps in the *Apc^{Min}* mouse arise between 1 and 3 mo of age (26, 33). Because polyp multiplicity at 3 mo of age highly depends on normal *Egfr* signaling, 1-mo-old *Apc^{Min}* mice were examined to distinguish between *Egfr*-dependent effects on initiation and establishment of the polyps. H&E-stained ileal sections from *Apc^{Min}* mice segregating *Egfr* alleles were analyzed for microadenomas based on crypt architecture and nuclear cytology (Fig. 2A). Adenomatous crypts were abnormally large and frequently cystically dilated or otherwise distorted, occasionally containing eosinophilic granular debris. Nuclear to cytoplasmic ratio was increased in adenomatous cells, nuclei were crowded and overlapping, and apoptotic bodies were increased. All microadenomas identified morphologically also exhibited strong nuclear β -catenin immunoreactivity (Fig. 2B), supporting their classification as adenomatous lesions and suggesting that impaired *Egfr* activity does not alter β -catenin transit into the nucleus, an early consequence of Apc loss (29, 34). To identify microadenomas not scored morphologically, β -catenin-labeled ileal sections were examined for clusters of cells exhibiting nuclear β -catenin localization in nondistorted crypts (Fig. 2C–E). β -catenin-positive nuclei were located in clusters of contiguous cells above the proliferative zone in crypts but did not extend up the villus.




Fig. 2. Early ileal lesions in *Apc^{Min}* mice. (A and B) Adjacent sections of an *Egfr⁺* cystic microadenoma. (C) *Egfr⁺* crypt, containing a cluster of three nuclear β -catenin-positive cells, flanked by normal crypts. (D) Close up of boxed crypt from C. (E) *Egfr^{wa2}* crypt with several β -catenin-positive nuclei. (A) H&E staining. (B–E) β -catenin immunohistochemistry. Arrowheads in D mark the β -catenin-positive nuclei.

On adjacent H&E-stained sections, these crypts exhibited only subtle architectural distortion with slight increases in nuclear to cytoplasmic ratio, apoptotic bodies, granular eosinophilic debris, and mixed inflammatory infiltrate in adjacent lamina propria. The difference in total microadenoma number (combined non-overlapping morphological and normalized nuclear β -catenin counts) between wt *Egfr* and *Egfr^{wa2}* mice was not statistically significant (0.42 ± 0.31 vs. 0.34 ± 0.32 microadenoma/slide, $P = 0.50$; Fig. 1B), suggesting that *Egfr* is required for intestinal polyp development after morphological initiation. Likewise, no difference in microadenoma architecture was seen based on *Egfr* status. No morphological microadenomas and a single β -catenin-positive nucleus were detected in ileal sections from wt *Apc* control littermates ($n = 3$), supporting the *Apc^{Min}* dependency of these lesions.

***Egfr*-Independent Intestinal Adenoma Growth.** To assess the importance of *Egfr* on net tumor growth, polyp diameter was measured from a randomized set of 3-mo-old *Apc^{Min}* mice on wt *Egfr* or *Egfr^{wa2}* backgrounds (Fig. 3A). Surprisingly, polyps forming on the *Egfr^{wa2}* background were slightly larger than those forming on the wt *Egfr* background (1.10 ± 0.58 mm vs. 1.03 ± 0.77 mm; $P = 0.024$), suggesting that rate of polyp expansion was not




Fig. 3. Intestinal polyp sizes in *Apc*^{Min} mice with reduced *Egfr* activity. (A) Genetic analysis. Solid and dashed lines indicate best linear fit of polyp diameter vs. age for 16 *Egfr*⁺ and 20 *Egfr*^{wa2} mice, respectively. Closed (*Egfr*⁺) and open (*Egfr*^{wa2}) circles indicate diameter means at each time point. (B) Pharmacological analysis. Dots represent individual polyp diameters from DMSO-treated (controls; *n* = 5) and EKI-785-treated (treatment; *n* = 5) mice. Means are represented by horizontal lines.

hindered by reduced *Egfr* activity. Alternatively, these results could be attributed to *Egfr*-dependent differences in growth rate masked by temporal differences in initiation or establishment. To distinguish these two possibilities, polyp size was measured in a cohort of 4- to 12-mo-old mice segregating *Egfr* genotypes. A linear regression of polyp diameter vs. age was performed to detect *Egfr*-dependent differences in polyp growth rates; polyps from *Apc*^{Min} mice have previously been reported to grow linearly (33). The linear fits of the two data sets show no significant difference in slope value (*Egfr*^{wa2/wa2} 0.11, *Egfr*^{wa2/+} 0.13; *P* = 0.59), suggesting that the reduced activity of the *Egfr*^{wa2}-encoded receptor does not alter net growth rate of established polyps. Of interest, marker analysis suggests a slight expansion of the proliferative compartment in normal *Egfr*^{wa2} crypts compared to wt crypts (Ki67-labeled nuclei: *Egfr*^{wa2/wa2} 23.9 ± 0.87, *Egfr*^{wa2/+} 20.0 ± 1.3, *P* = 0.014; [³H]thymidine incorporated nuclei: *Egfr*^{wa2/wa2} 9.9 ± 2.2, *Egfr*^{wa2/+} 7.0 ± 1.0, *P* < 0.0001).

Pharmaceutical Inhibition of Intestinal Adenoma Growth. Previous conflicting reports used irreversible small molecule *Egfr* kinase inhibitors in the *Apc*^{Min} mouse model. Although no effect on tumorigenesis was observed by using CFPQA (25), in a separate study EKI-785 was found to reduce *Apc*^{Min} tumor multiplicity by ≈50% after treatment from 1 to 3 mo of age (24). To confirm the results obtained with the *Apc*^{Min}, *Egfr*^{wa2} animals, we used a similar EKI-785 treatment regimen in *Apc*^{Min} animals. Although we used i.p. rather than oral dosing, as previously reported, we saw a 60% reduction in polyp number in the EKI-treated cohort at 3 mo of age (treated: 6.3 ± 2.9; controls: 15.0 ± 6.3; *P* = 0.047; *n* = 5 mice/group). Supporting the genetic studies, no difference was observed in average polyp diameter between EKI-785-treated and control animals (0.89 ± 0.24 mm and 0.88 ± 0.28 mm; *P* = 0.76; Fig. 3B).

EGFR-Dependent Human Colon Cancer Xenograft Growth. To address the role of EGFR signaling at later stages of tumor growth, EKI-785 was administered to athymic mice carrying 150-mm³ s.c. tumors derived from injection of two human colorectal cancer (CRC) cell lines, HCA-7 and HCT-116. Both lines exhibit constitutive EGFR phosphorylation under baseline conditions, suggesting the presence of an active EGFR autocrine loop. However, exogenous application of the EGFR ligand transform-




Fig. 4. Growth curves of human CRC cell line xenografts in nude mice treated with EKI-785. Volumes of tumors derived from HCA-7 (A) and HCT-116 (B) cells. EKI-785 doses (mg/kg body weight) are given at the end of each growth curve.

ing growth factor α stimulates the *in vitro* growth of the HCA-7 line, whereas HCT-116 is resistant because of saturating levels of transforming growth factor α that are 22-fold higher than the HCA-7 line (E. Chung and R.J.C., unpublished data). Doses of EKI-785 as low as 25 mg/kg reduced the growth of HCA-7 cells, and a dose of 100 mg/kg prevented tumor growth entirely (Fig. 4A). Also, a dose of 50 mg/kg EKI-785 was effective at reducing growth of HCT-116 cells (Fig. 4B). These findings suggest that EGFR signaling, in addition to affecting the establishment phase of intestinal tumorigenesis, also contributes to late-stage tumor growth.

Discussion

Although gain- or loss-of-function mutations in *Egfr* are not consistently found in specific epithelial tumor types, circumstantial evidence has accumulated suggesting that *Egfr* activity can modulate the initiation and progression of epithelial-derived tumors (17, 19). Indirect evidence derived from *in vitro* studies of GI cancer cell lines also suggest an important role for *Egfr* in intestinal tumorigenesis (18, 20). By placing the *Apc*^{Min} mouse model of familial adenomatous polyposis on an *Egfr*^{wa2} background, we were able to examine intestinal polyp development *in vivo* in a genetic environment of reduced *Egfr* kinase activity. Despite a heterogeneous genetic background, the *Egfr*^{wa2} allele had a profound effect on polyp number in adult animals, reducing mean tumor number 90%. This reduction mirrors the reported 10-fold reduction in kinase activity in the *Egfr*^{wa2}-encoded protein (5). In fact, the majority of *Egfr*^{wa2} mice had zero or only one intestinal tumor. Careful histologic examination of younger, 4-wk-old animals showed no significant difference between *Egfr* genotypes in the numbers of microadenomas or nuclear β -catenin-positive cell clusters, which are the earliest detectable morphologic and molecular lesions in *Apc*-mediated tumorigenesis. Interestingly, the size, growth rate, and morphology of the polyps examined in adult animals were not altered by *Egfr* status, a surprising result given that *Egfr* has been shown to mediate many of the cellular functions that are misregulated during tumorigenesis, including proliferation, differentiation, migration, and survival.

Our experiments are timely given recent contradictory reports on the requirement for *Egfr* signaling in intestinal tumor development (24, 25). Similar to the results reported here, Torrance, *et al.* (24) observed that two *Egfr* kinase inhibitors, EKI-785 and EKB-569, produced a significant reduction in *Apc*^{Min} polyp number. In contrast, Ritland, *et al.* (25) did not observe a reduction in *Apc*^{Min} polyp multiplicity by using the irreversible *Egfr* kinase inhibitor CFPQA. Experiments in both reports provided EKI treatment from 1 to 3 mo of age. Neither study examined the temporal requirement for *Egfr* in tumor development, and more importantly in relation to potential chemother-




Fig. 5. Model of Egfr activity requirements during intestinal tumorigenesis. Red dots represent nuclear β -catenin-positive cells. Solid green lines indicate evidence for Egfr activity during establishment and adenocarcinoma expansion. Dashed green lines indicate that a requirement for Egfr activity during adenoma expansion, progression, and invasion has yet to be demonstrated conclusively.

apeutic use of Egfr inhibitors, these reports did not address the continued dependency on Egfr signaling for tumor expansion. Furthermore, although EKI-785 and EKB-569 both have Egfr as their primary affinity target, they also are known to affect secondary targets such as ErbB2 and Src, and potentially may affect other, unknown targets as well (22, 24). Our genetic approach directly demonstrates that Egfr is required for intestinal tumor development, thus providing resolution to previous conflicting pharmaceutical studies and confirming Egfr as a valid therapeutic target. However, our results also pose considerable new questions that must be addressed, especially in light of clinical trials using Egfr inhibition as CRC treatment.

Our genetic results suggest that a threshold level of Egfr activity is transiently required after loss of *Apc* and morphological development of microadenomas but before microadenomas become established and expand into macroadenomas. This model defines a role for Egfr in an establishment stage during intestinal tumorigenesis when nascent tumors are highly susceptible to being lost (Fig. 5). Nascent microadenomas that are unable to pass through this establishment phase may senesce, be resorbed, or be lost into the intestinal lumen. Tumors on the *Egfr^{wa2}* background may become established when levels of Egfr activity stochastically breach the threshold level in cells that are already initiated by means of *Apc* loss. Once the threshold is achieved, downstream effects could maintain the threshold activity level, or alternatively, tumorigenic events induced by the threshold activity could continue independent of Egfr. This stochastic, Egfr activity-correlated model would predict that further reductions in Egfr activity would produce a similar reduction in polyp multiplicity.

A strong alternative explanation for the profound *Egfr*-dependent reduction in polyp multiplicity may be that Egfr activity in *Egfr^{wa2}* mice is sufficiently below the required threshold such that stochastic fluctuations do not breach the required level; a possibility supported by the observation that *Egfr^{wa2/wa2}* mice develop the same number of macroadenomas as *Egfr^{wa2/tm1Mag}* mice, even though the latter presumably have lower net Egfr activity. Rather, the few polyps that develop in *Egfr^{wa2}* mice, despite being pathologically similar to polyps developing in wt *Egfr* mice, may rely on perturbation of other signaling pathways for their growth and survival. The latter case

is partially supported by the fact that the few polyps forming on the *Egfr^{wa2}* background seem to expand in an Egfr-independent manner. Albeit mechanistically different, a similar finding distinguished tumors arising on *Mom1^r* and *Mom1^s* backgrounds, where two molecularly different pathways for *Apc* loss have been identified that result in pathologically indistinguishable polyps (35).

Previous studies (24, 25) examined the effects of EKI treatment on the phenotype of C57BL/6J-*Apc^{Min}* mice, which are homozygous for the *Mom1^s* allele. The animals used in our genetic studies were segregating the *Mom1^r* and *Mom1^s* alleles in addition to the various *Egfr* alleles, and our data suggest potential synergy between the *Egfr^{wa2}* and *Mom1^r* alleles. However, the mixed genetic background is likely segregating unknown modifiers of polyp multiplicity, suggested by the presence of two outliers in the *Egfr^{wa2}* class (Fig. 1A). These animals phenotypically resemble animals carrying a wt allele of *Egfr*, in part demonstrating the potential for multiple susceptibility alleles in the genetic background overcoming the effects of a strong modifier such as *Egfr^{wa2}*. Because the *Mom1^r* background is putatively more representative of the human population than the mouse-specific *Mom1^s* background, any synergy between reduction of Egfr activity and *Mom1^r* should further the efficacy of Egfr inhibition as therapy for human cancers.

A pattern of Egfr action is emerging from studies of epithelial-stromal interactions during organ development and growth. Tissue recombination experiments support a stromal requirement for Egfr activity in epithelial organ growth and patterning, whereas epithelial Egfr activity appears dispensable for these functions (36, 37). In this model, epithelial growth is regulated in part by means of Egfr-mediated signaling from the stromal compartment. Epithelial tumors may require an event such as spatial misexpression of *Egfr* or its ligands to uncouple epithelial proliferation and patterning from stromal control. Extensive morphological studies of polyp formation in *Apc^{Δ716}* mice reveal a complex architectural transition from early microadenoma to macroadenoma during the establishment phase of tumorigenesis (38, 39). The transition involves the invagination of dysplastic epithelium into the stromal center of a single villus, with the nascent microadenoma spreading into neighboring villi, growing under the normal gut epithelium. Thus the establishment stage of *Apc^{Min}* polyp formation involves movement of the dysplastic cell population out of the lumen and into an environment of stromal interaction. Ability of the stroma to support epithelial survival and proliferation in this abnormal state may require a level of Egfr activity above that provided by the *Egfr^{wa2}*-encoded receptor. Egfr activity has also been implicated in regulation of tumor cell adhesion by means of E-cadherin complexes (40, 41); it may be possible that wt Egfr activity is necessary to allow cell adhesion states that permit the complete and continued establishment of the microadenoma in the adjacent normal tissue. Outside the local environment the tumor may not survive, may be exposed to growth inhibitory factors, or may be lost into the lumen of the gut.

The proposition that reduction of Egfr activity affects early establishment of intestinal tumors, while seemingly having no affect on established polyp growth, seems to contraindicate use of Egfr inhibitors as chemotherapeutics for human CRC. To test the potential efficacy of Egfr inhibition for reduction of human CRC growth, mice carrying xenografts of human colon cancer cell lines were treated with EKI-785. We observed significant dose-dependent reduction in the growth rate and final tumor volume in treated mice relative to controls, and expansion of tumors seeded from the HCA-7 cell line was abrogated with an EKI-785 dose of 100 mg/kg. These cell lines represent more advanced tumors than adenomas forming in *Apc^{Min}* mice. Thus Egfr activity may be required during later stages of intestinal tumor progression, a possibility supported by evidence correlat-

ing high levels of *Egfr* expression with invasive and metastatic cancer potential (18, 20, 42).

Although initially our pharmacologic data may contradict our genetic data, there are major differences in the reduction of *Egfr* activity both temporally and in kind. The *Apc^{Min}, Egfr^{wa2}* animals experience a reduction of *Egfr* activity from conception, whereas EKI-785 treatment reduces *Egfr* activity in xenografts of established, progressed tumor cell lines. Also, the mutant receptor encoded by the *Egfr^{wa2}* mutation has reduced signaling capacity because of a conformational alteration of the kinase domain. This is a very different situation than EKI-785 inhibition, which causes permanent inactivation of the receptors it targets; EKI-inhibited cells retain the ability to produce more wt receptors with full signaling capacity. It is likely that both normal and transformed cells would adapt very differently to these two forms of *Egfr* reduction. The effects of EKI-785 treatment seen in xenograft tumors may be caused by an established dependence on *Egfr* signaling. In *Apc^{Min}, Egfr^{wa2}* animals, effects on polyp expansion and survival beyond establishment may not be observed because the subset of polyps forming on that background have by necessity arisen in an *Egfr*-independent manner. Perhaps further reduction of *Egfr*

activity beyond that provided by the *Egfr^{wa2}* mutation could inhibit growth of even this subset of polyps.

Egfr kinase inhibition may prove to be a potent therapy in all stages of colon carcinogenesis; however, our data suggests judicious use at discrete stages. Furthermore, our results suggest that a subset of *Apc*-mediated intestinal polyps will not respond to *Egfr* inhibition. Also, long-term EKI treatment in humans may recapitulate the results seen in *Apc^{Min}, Egfr^{wa2}* animals; that is, some tumors may adapt by becoming *Egfr*-independent, much as prostate tumors progress to androgen independency after surgical or chemical castration (43, 44). The latter concern would be especially relevant to the use of EKIs as extended preventative treatment for genetically predisposed individuals such as familial adenomatous polyposis kindreds. Continued elucidation of the mechanism by which *Egfr* signaling contributes to intestinal tumorigenesis, combined with the advent of genetic profiling of tumors, may allow the specific identification of those tumors that will respond to EKI treatment.

We thank members of our laboratories for valuable suggestions and Dr. Fei Zou for statistical analysis of the *Mom1–Egfr* interaction. This research was supported by Grants CA092479, CA084239, and CA046413 from the National Cancer Institute.

- Gullick, W. J. (1998) *Biochem. Soc. Symp.* **63**, 193–198.
- Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C., Mourtou, T., Herrup, K., Harris, R. C., et al. (1995) *Science* **269**, 230–234.
- Sibilia, M. & Wagner, E. F. (1995) *Science* **269**, 234–238.
- Miettinen, P. J., Berger, J. E., Meneses, J., Phung, Y., Pedersen, R. A., Werb, Z. & Derynck, R. (1995) *Nature (London)* **376**, 337–341.
- Luetke, N. C., Phillips, H. K., Qiu, T. H., Copeland, N. G., Earp, H. S., Jenkins, N. A. & Lee, D. C. (1994) *Genes Dev.* **8**, 399–413.
- Fowler, K. J., Walker, F., Alexander, W., Hibbs, M. L., Nice, E. C., Bohmer, R. M., Mann, G. B., Thumbwood, C., Maglito, R., Danks, J. A., et al. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 1465–1469.
- Helmrath, M. A., Erwin, C. R. & Warner, M. D. (1997) *J. Surg. Res.* **69**, 76–80.
- Egger, B., Buchler, M. W., Lakshmanan, J., Moore, P. & Eysselein, V. E. (2000) *Scand. J. Gastroenterol.* **35**, 1181–1187.
- Park, H. S., Goodlad, R. A., Ahnen, D. J., Winnett, A., Sasieni, P., Lee, C. Y. & Wright, N. A. (1997) *Am. J. Pathol.* **151**, 843–852.
- Umekita, Y., Ohi, Y., Sagara, Y. & Yoshida, H. (2000) *Int. J. Cancer* **89**, 484–487.
- Dassonville, O., Formento, J. L., Francoual, M., Ramaioli, A., Santini, J., Schneider, M., Demard, F. & Milano, G. (1993) *J. Clin. Oncol.* **11**, 1873–1878.
- Tewari, K. S., Kyshtoobayeva, A. S., Mehta, R. S., Yu, I. R., Burger, R. A., DiSaia, P. J. & Fruehauf, J. P. (2000) *Gynecol. Oncol.* **78**, 130–136.
- Barnard, J. A., Graves-Deal, R., Pittelkow, M. R., DuBois, R., Cook, P., Ramsey, G. W., Bishop, P. R., Damstrup, L. & Coffey, R. J. (1994) *J. Biol. Chem.* **269**, 22817–22822.
- Dlugosz, A. A., Hansen, L., Cheng, C., Alexander, N., Denning, M. F., Threadgill, D. W., Magnuson, T., Coffey, R. J. & Yuspa, S. H. (1997) *Cancer Res.* **57**, 3180–3188.
- Hansen, L. A., Woodson, R. L., II, Holbus, S., Strain, K., Lo, Y. C. & Yuspa, S. H. (2000) *Cancer Res.* **60**, 3328–3332.
- Sibilia, M., Fleischmann, A., Behrens, A., Stingl, L., Carroll, J., Watt, F. M., Schlessinger, J. & Wagner, E. F. (2000) *Cell* **102**, 211–220.
- Messa, C., Russo, F., Caruso, M. G. & Di Leo, A. (1998) *Acta Oncol.* **37**, 285–289.
- Tong, W.-M., Ellinger, A., Sheinin, Y. & Cross, H. S. (1998) *Br. J. Cancer* **77**, 1792–1798.
- Hayashi, Y., Widjono, Y. W., Ohta, K., Hanioka, K., Obayashi, C., Itoh, K., Imai, Y. & Itoh, H. (1994) *Pathol. Int.* **44**, 124–130.
- Radinsky, R., Risin, S., Fan, D., Dong, Z., Bielenberg, D., Bucana, C. D. & Fidler, I. J. (1995) *Clin. Cancer Res.* **1**, 19–31.
- Noonberg, S. B. & Benz, C. C. (2000) *Drugs* **59**, 753–767.
- Discafani, C. M., Carroll, M. L., Floyd, M. B., Jr., Hollander, I. J., Husain, Z., Johnson, B. D., Kitchen, D., May, M. K., Malo, M. S., Minnick, A. A., Jr., et al. (1999) *Biochem. Pharmacol.* **57**, 917–925.
- Sweeney, W. E., Chen, Y., Nakanishi, K., Frost, P. & Avner, E. D. (2000) *Kidney Int.* **57**, 33–40.
- Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B., Wissner, A., Nunes, M., Frost, P. & Discafani, C. M. (2000) *Nat. Med.* **6**, 1024–1028.
- Ritland, S. R., Gendler, S. J., Burgart, L. J., Fry, D. W., Nelson, J. M., Bridges, A. J., Andress, L. & Karnes, W. E. (2000) *Cancer Res.* **60**, 4678–4681.
- Moser, A. R., Pitot, H. C. & Dove, W. F. (1990) *Science* **247**, 322–324.
- Cormier, R. T., Bilger, A., Lillich, A. J., Halberg, R. B., Hong, K. H., Gould, K. A., Borenstein, N., Lander, E. S. & Dove, W. F. (2000) *Oncogene* **19**, 3182–3192.
- Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B. & Clevers, H. (1997) *Science* **275**, 1784–1787.
- Iwamoto, M., Ahnen, D. J., Franklin, W. A. & Maltzman, T. H. (2000) *Carcinogenesis* **21**, 1935–1940.
- Dietrich, W. F., Lander, E. S., Smith, J. S., Moser, A. R., Gould, K. A., Luongo, C., Borenstein, N. & Dove, W. (1993) *Cell* **75**, 631–639.
- Marsh, K. A., Stamp, G. W. & Kirkland, S. C. (1993) *J. Pathol.* **170**, 441–450.
- Chinery, R., Brockman, J. A., Peeler, M. O., Shyr, Y., Beauchamp, R. D. & Coffey, R. J. (1997) *Nat. Med.* **3**, 1233–1241.
- Gould, K. A., Dietrich, W. F., Borenstein, N., Lander, E. S. & Dove, W. F. (1996) *Genetics* **144**, 1769–1776.
- Sheng, H., Shao, J., Williams, C. S., Pereira, M. A., Taketo, M. M., Oshima, M., Reynolds, A. B., Washington, M. K., DuBois, R. N. & Beauchamp, R. D. (1998) *Carcinogenesis* **19**, 543–549.
- Shoemaker, A. R., Moser, A. R., Midgley, C. A., Clipson, L., Newton, M. A. & Dove, W. F. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 10826–10831.
- Wiesen, J. F., Young, P., Werb, Z. & Cunha, G. R. (1999) *Development (Cambridge, U.K.)* **126**, 335–344.
- Hom, Y. K., Young, P., Wiesen, J. F., Miettinen, P. J., Derynck, R., Werb, Z. & Cunha, G. R. (1998) *Endocrinology* **139**, 913–921.
- Oshima, M., Oshima, H., Kitagawa, K., Kobayashi, M., Itakura, C. & Taketo, M. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 4482–4486.
- Oshima, H., Oshima, M., Kobayashi, M., Tsutsumi, M. & Taketo, M. M. (1997) *Cancer Res.* **57**, 1644–1649.
- Hazan, R. B. & Norton, L. (1998) *J. Biol. Chem.* **273**, 9078–9084.
- Roura, S., Miravet, S., Piedra, J., Garcia de Herreros, A. & Dunach, M. (1999) *J. Biol. Chem.* **274**, 36734–36740.
- Gross, M. E., Zorbas, M. A., Danels, Y. J., Garcia, R., Gallick, G. E., Olive, M., Brattain, M. G., Boman, B. M. & Yeoman, L. C. (1991) *Cancer Res.* **51**, 1452–1459.
- Galbraith, S. M. & Duchesne, G. M. (1997) *Eur. J. Cancer* **33**, 545–554.
- Theyer, G. & Hamilton, G. (1998) *Urology* **52**, 353–359.